The official recommendations are that patients taking oral systemic anti-cancer therapy (SACT) receive the same level as care as those receiving intravenous SACT in a hospital setting. However, this poses many logistical challenges. In this interview, Michael Mawhinney of Oxford Brookes University, Oxford, UK, discusses his review of this issue, which was presented at the UK Oncology Nursing Society (UKONS) Annual Conference 2017 in Harrogate, UK.